- Drug discovery company C4X Discovery Holdings said it had entered into a collaboration with PhoreMost.

The collaboration, initially focused on Parkinson's disease, would combine both company's technology platforms.

'As part of our strategy to become the world's most productive drug discovery company, we continually assess cutting edge technologies that add to our current capabilities in target identification and drug design,' chief executive Clive Dix said.

'PhoreMost has one such technology with the potential to both validate targets and provide chemistry starting points for our molecular design platforms.'

'This partnership complements C4XD's existing target validation collaborations and enables us to accelerate our portfolio growth whilst decreasing the timelines in drug discovery.'

At 1:28pm: (LON:C4XD) C4x Discovery Holdings Plc share price was +0.5p at 51p

Story provided by